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Abstract
Purpose—African Americans (AA) have a higher incidence and lower survival from colorectal 
cancer (CRC) compared to European Americans (EA). In the present study, statewide, population-
based data from South Carolina Central Cancer Registry (SCCCR) is used to investigate the 
relationship between race and age on advanced stage CRC survival.
Methods—The study population was comprised of 3865 advanced pathologically documented 
colon and rectal adenocarcinoma cases diagnosed between 01 January 1996 and 31 December 
2006: 2673 (69%) EA and 1192 (31%) AA. Kaplan-Meier methods were used to generate median 
survival time and corresponding 95% confidence intervals (CI) by race, age, and gender. Factors 
associated with survival were evaluated by fitting Cox proportional hazards (CPH) regression 
models to generate Hazard Ratios (HR) and 95% CI.
Results—We observed a significant interaction between race and age on CRC survival (p = 
0.04). Among younger patients (< 50 years), AA race was associated with a 1.34 (95% CI 
1.06-1.71) higher risk of death compared to EA. Among older patients, we observed a modest 
increase risk of death among AA men compared to EA (HR 1.16 (95% CI 1.01-1.32) but no 
difference by race among women (HR 0.94 (95% CI 0.82-1.08)). Moreover, we observed that the 
disparity in survival has worsened over the past 15 years.
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Conclusions—Future studies that integrate clinical, molecular, and treatment-related data are 
needed for advancing understanding of the racial disparity in CRC survival, especially for those < 
50 years old.
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Introduction
Colorectal cancer (CRC) is the third most common malignancy in the US and the second 
leading cause of cancer death [1]. Compared to European Americans (EA), African 
Americans (AA) have a 20% higher CRC incidence rate and a 45% higher mortality rate [1]. 
At least some of the excess mortality in AA is caused by the reduced survival associated 
with a higher prevalence of metastatic disease at diagnosis [2-4]. However, the disparity 
persists at each stage and is likely to be influenced by differences in treatment utilization 
and/or CRC tumor biology.
CRC survival has improved significantly over the past fifteen years due to the introduction 
of several new chemotherapeutic agents; yet, the racial difference in survival has worsened, 
especially among advanced stage patients [5, 6]. Until the year 2000, there were few 
treatment options other than 5-Fluorouracil (5-FU) and leuvocourin for metastatic CRC; 
however, with the introduction of combination chemotherapy in 2000 (i.e., irinotecan or 
oxaliplatin with 5-FU) and the addition of biologic agents to the combination chemotherapy 
in 2004 (i.e., bevacizumab or cetuximab), the median survival has increased from 8-12 
months in the mid-1990’s to 18-24 months in 2008 [7]. Although few studies have examined 
the effect of the new therapies on CRC survival at the population level, historical evidence 
suggests that AA may not experience the same survival benefit as EA [5, 8, 9]. To explain, 
AA have been reported to have lower rates of initiation of standard therapy [10-12] and 
refuse therapy at a higher rate than EA [13, 14]. More recently, AA have been found to have 
a lower response to the newer treatment regimens, which may translate to differences in 
survival by race [8, 15].
Differences in CRC tumor biology by race, age, and or gender may influence the difference 
in stage-specific survival. AA compared to EA are more likely to present at diagnosis at a 
younger age and with features indicative of greater tumor aggressiveness, including a higher 
proportion of proximal compared to distal neoplasia (11-17). Proximal colonic location is 
associated with worse survival [16-19], especially among advanced stage CRC patients. 
Earlier age of onset, irrespective of race, is associated with aggressive tumor histopathology, 
a higher grade and stage of CRC, and a higher proportion of hereditary CRC [20-27]. 
Furthermore, gender may also be associated with difference in tumor aggressiveness since 
women appear to have a tendency to develop tumors with lower rates of metastasis and 
better prognosis [28, 29]. However, few studies have considered the intersection of race, age 
and gender on survival.
In the present investigation, statewide, population-based data from South Carolina Central 
Cancer Registry (SCCCR) is used to examine if there are racial differences in survival in 
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advanced stage CRC. This study is restricted to a single stage because the magnitude of the 
racial disparity in survival has been shown to differ by stage. This study focuses on 
metastatic disease because of similar recommended standard therapy, large racial difference 
in the relative survival, and a documented change in chemotherapy usage in both 2000 and 
2004. We investigated the relationship between race and age on CRC survival during three 
calendar periods: (1) 1996-1999; (2) 2000-2003; and (3) 2004-2006, each corresponding to a 
change in chemotherapeutic regimen. We also explored the influence of clinicopathologic 




The study population was comprised of 3865 advanced pathologically documented colon 
and rectal adenocarcinoma cases in South Carolina diagnosed between 01 January 1996 and 
31 December 2006: 2673 (69%) EA and 1192 (31%) AA. For analyses of time-to-death, 402 
subjects - 267 (66%) EA subjects and 135 (34%) AA subjects --could not be included 
because no survival time data were available, resulting in 3463 subjects available for 
survival analyses.
Patient cancer stage was coded using SEER staging criteria: local, regional, or distant. The 
present study was limited to patients who presented with distant disease (i.e. distant lymph 
nodes or distant sites); distant disease is equivalent to TNM stage IV. The SCCCR is a 
population-based, mandated data system that collects cancer incidence in South Carolina. 
Information on cancer mortality (deaths) is collected by the Division of Vital Registry and 
published by the Division of Biostatistics and Division of Public Health Informatics within 
the Department of Health and Environmental Control. For every case, data were collected on 
age, race (white, black, Hispanic, Asian, or other), gender, first-line chemotherapy treatment 
(yes or no), and year of diagnosis and death. Our analysis is restricted to EA and AA due to 
the low number of patients from other racial/ethnic groups.
Clinicopathologic characteristics
The clinicopathologic characteristics for each primary tumor include location, tumor grade, 
and histological type. The primary tumor was characterized according to the location within 
the colorectum: cecum, ascending colon, appendix, hepatic flexure, transverse colon, 
splentic flexure, descending colon, sigmoid colon, recto-sigmoid, or rectum. The tumor was 
grouped as proximal (cecum, ascending colon, appendix, hepatic flexure transverse colon), 
distal (splentic flexure, descending colon, sigmoid colon) or rectal (recto-sigmoid, or 
rectum).
Additionally, tumor grade was classified as well-differentiated, moderately differentiated, 
poorly differentiated, or undifferentiated. For the main analyses, tumor grade was 
dichotomized into low grade (well differentiated, moderately differentiated) and high grade 
(poorly differentiated, undifferentiated). Histological type was classified as adenocarcinoma 
not otherwise specified, mucinous adenocarcinoma, or signet ring cell adenocarcinoma.
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Survival time was calculated as the time from diagnosis with distant stage CRC to death 
from any cause from 1 January 1996 through 31 December 2007; subjects alive as of this 
date were censored at the end of follow-up. Kaplan-Meier methods were used to generate 
median survival time and corresponding 95% confidence intervals by race, age, and gender 
for subjects diagnosed in three time periods: (1) before 31 December 1999, (2). between 01 
January 2000 and 31 December 2003 (inclusive), and (3) on or after 01 January 2004, time 
intervals that were selected to correspond to changes in recommended systematic 
chemotherapy regimens.
Factors associated with survival were evaluated by fitting Cox proportional hazards (CPH) 
regression models. First, we explored the possibility of interaction between race and age by 
fitting separate CPH models for each age group in five-year increments, with race as the 
independent variable. We then examined smoothed scatter plots of the resulting estimated 
log cumulative hazards by age separately for AA and EA, and detected a highly non-linear 
effect. Graphically, the log cumulative hazards were relatively flat for ages under 50 years, 
but then increased linearly for increasing age thereafter (figure not shown). A CPH 
multivariable model fit using a three-knot restricted cubic spline transformation of age 
indicated significant nonlinearity (p = 0.01). Furthermore, there was evidence of significant 
interaction between age (modeled non-linearly), race and gender (p = 0.04). Therefore, we 
performed stratified analyses for patients both under and over 50 years of age to aid in 
interpretability of results.
We subsequently fit separate CPH regression models for younger patients (under the age of 
50 years) and older patients (50 years of age and older). For each model, we included main 
effects for location, grade, histologic type, age (continuous and linear), race, gender, first-
line chemotherapy initiation, and diagnosis year. Additionally, for each model, we examined 
twoway interactions between: 1) race and each of following: gender, diagnosis year, 
location, grade, histology; and 2) gender and each of following: diagnosis year, location, 




In the univariate analysis (Table 1), AA compared to EA were significantly more likely to 
be female and have proximal tumors. The prevalence of proximal tumors among African 
American men and women was 40% and 44% respectively, whereas the prevalence in 
European American men and women was 26% and 33% respectively. No differences were 
observed by race for tumor grade, histologic type, first-line chemotherapy, or year of 
diagnosis.
For the patients in our sample, the median follow up time was 15 months (range = 1 to 141 
months). Median survival improved significantly between 1996 and 2007 for both AA and 
EA but the improvement in survival differed by race (Table 2). The gain in median survival 
months was 262% greater in EA compared to AA men and 200% greater in EA women 
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compared to AA women. During the study period, a growing racial disparity was evident 
among the younger aged-patients, especially among women. Prior to the year 2000, there 
was 6.5 month difference in survival between AA and EA women which had widened to an 
11 month difference by the end of the follow-up period. Among men, however, the racial 
disparity was only evident after 2003. AA men had a 2 month survival advantage in time 
frame before 2000 which had changed to an 11 month lower survival by the end of follow-
up.
In multivariable Cox proportional hazard analyses, overall survival was significantly poorer 
among African Americans (p=0.02), high tumor grade (p=0.001), adenocarcinoma 
histological type (p=0.04), and pre-2000 year of diagnosis (p=0.01) (Table 3). In addition to 
these main effects, an interaction was identified between gender and tumor location (p=0.01) 
whereby among women proximal location was associated with a 45% (95% CI 3%-105%) 
increased risk of death compared to those with distal tumors but in contrast among men, 
both proximal and rectal tumor location were associated with better survival compared to 
distal location.
Over age 50
In the univariate analysis (Table 1), AA compared to EA were significantly more likely to 
have proximal tumors (p = 0.023) and have a lower tumor grade (p=0.01). There were no 
differences in proximal location between AA (48%) and EA (51%) women, but both groups 
had a higher prevalence of proximal tumors compared to those less than 50 years of age. 
Among AA men, however, the prevalence of proximal carcinomas at diagnosis was 45% 
and only 35% for EA men. No differences were observed by race for gender, histologic 
type, first-line chemotherapy initiation, or year of diagnosis.
For older patients, the median follow up time was 12 months (range = 1 to 143 months). 
Median survival improved modestly from 1996 through the end of follow-up (Table 2). 
Overall, median survival improved for all patient groups. EA men had a 20% greater 
improvement in survival compared to AA men yet EA and AA women had equivalent 
improvements. During the study period, a marginal racial disparity emerged recently among 
men. Prior to the year 2003, there was no significant racial disparity among patients 50 years 
or older but by the end of follow-up there was a statistically significant difference in survival 
(p< 0.02).
In multivariable Cox proportional hazard analyses, factors significantly associated with 
worse survival were older age (p < 0.0001), not initiating first-line chemotherapy (p < 
00001), higher tumor grade (p < 0.0001), proximal tumor location (p < 0.0001), rectal 
location (p=0.041), and diagnosis pre-2000 (p=0.02). Furthermore, there was an interaction 
between gender and race (p =0.04) on overall survival (Table 3), which was based on the 
observation that among men, AA were 16% (95% CI 1%-32%) more likely to die compared 
to EA yet no difference was observed among women.
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In this analysis of South Carolina Central Cancer Registry (SCCCR) data, key findings were 
that AA had worse overall survival for advanced stage colorectal cancer. This racial 
disparity was largely concentrated among CRC patients under 50 years of age. A 
disconcerting observation was that the racial disparity has worsened during the past 15 
years. In the survival analysis, we observed that among the younger patients, AA had worse 
survival especially AA females with proximal tumors. For older patients, AA males had 
worse survival, but the association with race was not nearly as pronounced as it was in the 
younger age groups.
Despite improvements in survival among those with advanced stage CRC, our study 
highlights the high fatality rate of this disease, and thus emphasizing the importance of 
prevention and early detection of CRC. In the present study, there were a higher percentage 
of stage IV CRC cases under the age of 50 years in AA than EA (17% vs. 12%) and the 
prognosis of AA patients was worse suggesting a more aggressive phenotype. This touches 
on the broader issue of developing strategies for identifying high-risk patients who have not 
yet reached the age for recommended screening. These findings are thus in line with the 
recommendations of two national organizations that recommend AA begin CRC screening 
earlier than EA, 40 [30] or 45 [31] years of age.
Our findings of poorer CRC survival in AA compared to EA parallel those of several 
previous investigations. Our finding that the disparity among late stage CRC patients is 
largely concentrated among the younger patients is novel. In general, the racial disparity has 
been shown to occur at each stage for both men and women and has worsened during the 
past 40 years (23). Most (10, 24-34), but not all (35-37), studies have observed that the 
disparity persists even after adjustment for variables such as age, sex, stage, socioeconomic 
status, insurance status, and in some studies pathologic characteristics. After accounting for 
these factors, the survival differences by race range from 8-50% across the various patients 
populations that have been studied. The reasons for this persistent racial disparity in CRC 
survival remain poorly understood. However, results from the present study suggest that the 
effect of ‘race’ on advanced stage disease survival is not uniform across the population. 
Factors such as patient’s age at diagnosis, gender, type of CRC, and date of diagnosis 
(possibly reflecting differences in treatment utilization) all influenced the relationship 
between race and survival.
On average, AA are known to be diagnosed with CRC at an earlier age (11, 12, 49), but to 
our knowledge there are no previous reports of racial differences in survival by age. A large 
body of evidence documents that CRCs in younger persons are more likely to have familial 
hereditary CRC and, independently of family history, are likely to have more advanced and 
aggressive tumors (41, 42 2008, 43, 44). Younger patients also appear to have more genome 
complexity (assessed as copy number aberrations), and higher P53 expression or mutation 
(41, 42, 45). Within our data, younger AA and EA had different tumor profiles. AA had a 
higher prevalence of proximally located (+13%), mucinous (+4%) and lower grade (+6%) 
CRCs at diagnosis. Whether this represents a unique phenotype associated with poorer 
survival will need further study. On the other hand, despite the presence of more aggressive 
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disease, many studies have shown that younger persons (predominantly EA) have better 
survival from CRC [20, 23, 24, 27]. Another possibility is that poor clinical performance 
status coupled with an aggressive phenotype added to the worse outcomes among AA, but 
we could not assess this in our dataset. Finally, the role of hereditary colon cancer in 
younger AA and its impact on survival is largely unexplored. Two studies have reported a 
higher prevalence of MSI-H tumors in AA – a common phenotype in familial CRC-- 
compared to historical controls and, in one, the tumors exhibited a different mutational 
pattern [32, 33].
Outcomes in our investigation differed by race and by sex. Similar to two recent studies [28, 
29], we observed that younger EA women had better survival than younger EA men. In the 
present study, however, young AA women had worse survival than younger EA women did. 
In part, the racial difference by gender in the young may be influenced by the colonic 
location of the CRC. For example, among younger women, proximal colonic location was 
associated with poorer survival and younger AA women had a higher prevalence of 
proximal tumors compared to EA (44% vs. 33%). For older women, there was no difference 
in prevalence of proximally located tumors by race (AA 48% vs. EA 50%) and no racial 
difference in survival. Several studies have shown that estrogen protects against CRC 
[34-36], and it is possible that a subset of younger EA women have a different hormonal 
profile compared to younger AA woman. A similar pattern of poorer survival and aggressive 
phenotypes has been observed in younger AA breast cancers patients [37, 38] compared to 
EA. Among advanced stage CRC patients older than 50 years, a modest increase in risk 
among AA men compared to EA was seen with no difference among women.
Many studies, like ours, have found that clinicopathologic characteristics influence survival. 
Similar to previous investigations [39-41], we observed the prevalence of proximally based 
tumors is higher in AA. As in the present study, several previous studies have previously 
observed that proximal colonic location is associated with worse survival [16-19, 42]. 
Compared to distal tumors, proximal colonic tumors were observed to be associated with 
greater mortality among stage IV CRC patients (HR 1.22; 95% CI 1.16-1.28)) [16]. 
However, proximal cancers are not uniform. A subset of proximal tumors is associated with 
favorable prognosis (i.e. MSI-H cancers). CRC is increasingly recognized as a 
heterogeneous disease, which can evolve through at least three distinct carcinogenic 
pathways [43-49]: (1) the chromosomal instability pathways (CIN), (2) The CpG methylator 
pathway-1 (CIMP-1) and (3) the CpG methylator pathway-2 (CIMP-2). The CIMP pathways 
predominate in the proximal colon and demonstrate CpG methylation. The CIMP-1 cancers 
tend to exhibit MSI-H (Microsatellite instability-high) status, BRAF mutations, and low 
levels of KRAS and p53 mutations and have good prognosis; CIMP-2 CRCs have a higher 
proportion of Microsatellite stability (MSS), more frequent KRAS mutations and poor 
prognosis. The CIN pathway tumors show distal predominance, APC, P53 mutations, MSS, 
and lack extensive CpG methylation and have average prognosis. Furthermore, a recent 
study has found that AA have a higher prevalence of KRAS mutations, and those with these 
mutations have poorer survival [50]. While personalized medicine will certainly focus 
effective treatment on a colon tumor’s molecular vulnerabilities, it may be some time before 
this knowledge can fully explain the disparities we observed in the present study. Future 
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studies that integrate detailed molecular genetic/epigenetic markers along with detailed 
treatment information may be of particular value.
The persistence of racial differences in survival within the same stage suggests that 
treatment differences may be at least part of the explanation for differences in survival [3, 
51]. Historically, many [3, 11, 51, 52], but not all, studies [14] have found that AA patients 
are less likely to receive standard recommended therapy, and refuse therapy at a higher rate. 
We observed no statistically significant differences in the initiation of chemotherpy by race, 
but did see striking improvements in survival among EA patients after the introduction of 
combination chemotherpy in 2000, and again with the introdution of bevacizumab to the 
standard of care in 2004. Treatment utilization is strongly influenced by access to high-
quality medical care. Medically underserved populations (including AA) are less likely to 
have equal access to the state-of-the art care, especially younger AA without health 
insurance [51]. As such, it may be that there is a racial disparity in the dissemination of the 
newer chemotherpies although a recent report did not observe this [15]. In health care 
settings where patients have equal access to care, the racial disparity in treatment utilization 
and outcomes is attenuated. In the Veterans Administration, for example, no significant 
differences by race were reported in rates of surgical resection, radiation therapy, or 
chemotherapy use. Although AA as compared to EA had modestly poorer survival [53], the 
disparity is less pronounced than commonly observed in population-based studies. However, 
treatment efficacy may also differ by race. Sanoff and colleagues [8] analyzed outcomes to 
combination chemotherapy within the context of a clinical trial and found that survival by 
race differed by type of treatment regimen. AA patients on FOLFOX or FOLFIRI had lower 
survival compared to EA, yet AA on IROX (i.e., no 5-FU) appeared to have better survival 
than EA. On the other hand, recently, Polite et al. [15] studied metastatic CRC patients who 
received bevacizumab within a community based setting and observed no difference in 
survival by race. In both of these studies, AA had significantly lower response rates. 
Because treatment regimen was not detailed in our data, it is difficult to assess the role of 
treatment use versus efficacy on survival by race. Furthermore, because we do not have 
information on the treatment medication administered to patients we cannot be certain that 
AA and EA actually received the same multi-drug regimens which, if different by race, 
could potentially contribute to some of the differences in survival.
Advantages of our study include a large, racially diverse population of patients with 
advanced stage colorectal cancer with careful characterization of demographic and 
pathologic characteristics and vital status. However, our study had a few limitations. First, 
we had no data on patient-level factors (such co-morbid conditions or lifestyle and 
behaviors) or detailed treatment regimen data, which confound or modify the association 
between race and CRC survival. Second, we did not have information on CRC specific 
deaths only on all cause mortality; however, because all of the patients had advanced stage 
CRC we expect that most of these people died a result of their disease. Finally, the setting in 
South Carolina may differ from other locales in ways that limit the generalizability of the 
study findings. For example, South Carolina has a high proportion of rural residents, which 
may introduce substantive differences in results compared to populations that are largely 
urban. In the future, it will be essential to see if our findings can be replicated in different 
populations, and future studies that integrate patient-level, clinical, molecular, and 
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treatment-related data hold promise for advancing understanding of the racial disparity in 
CRC survival.
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